TwinBeech Capital’s Health Catalyst HCAT Stock Holding History

TwinBeech Capital’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,451	Closed	-$665K	–	593
2022 Q1	$665K	Buy	+25,451	New	+$722K	0.03%	373

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

TwinBeech Capital's HCAT Position: Q2 2022 in Review

TwinBeech Capital sold out of Health Catalyst (HCAT) in Q2 2022, closing a stake of 25,451 shares — an estimated $665K sold.

TwinBeech Capital first reported a position in HCAT in Q1 2022 and held it in 1 quarter. The position peaked at $665K in Q1 2022. 180 funds tracked by Wall St. Rank hold HCAT as of Q2 2022.

TwinBeech Capital reported no remaining Health Catalyst position as of Q2 2022 after selling out during the quarter.
TwinBeech Capital sold 25,451 Health Catalyst shares in Q2 2022, an estimated $665K.
TwinBeech Capital first reported a position in Health Catalyst in Q1 2022 and held it in 1 quarter.
TwinBeech Capital's Health Catalyst position peaked at $665K in Q1 2022.
180 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2022.

Based on TwinBeech Capital's 13F filing for Q2 2022, filed 15 Aug 2022.